RxDoctor Payments Data

Erik Sitker, MD

Nephrology · Burbank, CANPI 1205931722

Payments from drug & device makers

$894in general payments, 2019–2025

Across 29 payments — averaging $30.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$293
  • Akebia Therapeutics Inc$136
  • Ardelyx, Inc.$119
  • Penumbra, Inc.$108
  • Boehringer Ingelheim$103
  • Amgen$76
  • plus $59 from 2 others

What the payments were for

  • Food & beverage$73782%
  • Education$15718%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$894 in reported general payments places this provider in the 40th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$750,879
Medicare patients
773
Services billed
6,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide44$110,358
JardianceEmpagliflozin38$38,369
XphozahTenapanor Hcl13$37,565
Sevelamer Hcl17$29,636
ProcritEpoetin Alfa25$27,801
ClinolipidFat Emulsion/Olive/Soy/Phospho74$26,310
FarxigaDapagliflozin Propanediol19$23,853
ProsolParenteral Amino Acid 20% No.1113$20,350
Cinacalcet Hcl18$18,139
AuryxiaFerric Citrate17$16,976
Sevelamer Carbonate55$15,510
LokelmaSodium Zirconium Cyclosilicate13$9,437
EliquisApixaban17$8,853
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$7,191
Calcium Acetate67$6,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$36$110,35844 claims
Boehringer IngelheimJardiance$103$38,36938 claims
AstraZenecaFarxiga, Lokelma$23$33,29032 claims
Akebia Therapeutics IncAuryxia$136$16,97617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,341 nephrology providers in California.

Other nephrology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →